专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07129034B2 Differentiation of whole bone marrow 有权
公开(公告)号：US07129034B2
公开(公告)日：2006-10-31
申请号：US10253759
申请日：2002-09-24
申请人： John S. Yu , Peter Kabos , Moneeb Ehtesham
发明人： John S. Yu , Peter Kabos , Moneeb Ehtesham
IPC分类号： C12N5/00 , C12N5/06 , C12N5/08 , C12N5/10
CPC分类号： C12N5/0623 , A61K35/12 , A61K38/00 , A61K48/00 , C12N2501/11 , C12N2501/115 , C12N2506/11 , C12N2506/1353 , C12N2510/00
摘要： A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.

2. 发明申请

US20110256555A1 USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL 审中-公开
标题翻译： CXCR4蛋白表达在干细胞表面上的应用作为肿瘤热点潜力的标记
公开(公告)号：US20110256555A1
公开(公告)日：2011-10-20
申请号：US13163553
申请日：2011-06-17
申请人： John S. Yu , Moneeb Ehtesham
发明人： John S. Yu , Moneeb Ehtesham
IPC分类号： C12Q1/02 , G01N33/53
CPC分类号： C12N5/0623 , C12N2501/11 , C12N2501/115 , G01N33/5017 , G01N33/5073 , G01N2333/715
摘要： The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1.
摘要翻译：本发明涉及肿瘤热带干细胞，特别涉及神经干细胞，以及它们作为治疗性基因产物转移至肿瘤灶的递送载体的用途。基于显示CXCR4受体的干细胞或对趋化因子SDF-1的亲和力，选择具有肿瘤嗜性潜能的干细胞。干细胞可能另外表现出星形细胞祖细胞特征的标志物。干细胞可以作为治疗方案的一部分施用，包括趋化因子SDF-1。

3. 发明授权

US08071366B2 Neural progenitor cells derived from whole bone marrow 有权
标题翻译：来自全骨髓的神经祖细胞
公开(公告)号：US08071366B2
公开(公告)日：2011-12-06
申请号：US11433996
申请日：2006-05-15
申请人： John S. Yu , Peter Kabos , Moneeb Ehtesham
发明人： John S. Yu , Peter Kabos , Moneeb Ehtesham
IPC分类号： C12N5/0797 , C12N5/074
CPC分类号： C12N5/0623 , A61K35/12 , A61K38/00 , A61K48/00 , C12N2501/11 , C12N2501/115 , C12N2506/11 , C12N2506/1353 , C12N2510/00
摘要： A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.
摘要翻译：描述了从全骨髓产生临床显着体积的神经祖细胞的方法。大量的骨髓细胞可以在补充有成纤维细胞生长因子-2（FGF-2）和表皮生长因子（EGF）的培养物中生长。本发明的其它方法涉及利用以这种方式培养的神经祖细胞来治疗各种神经病理学病症，并将靶向特定基因转染的细胞靶向递送给病变组织或受损组织。

4. 发明授权

US07504100B2 Method for delivering a biological compound using neural progenitor cells derived from whole bone marrow 有权
标题翻译：使用衍生自全骨髓的神经祖细胞递送生物化合物的方法
公开(公告)号：US07504100B2
公开(公告)日：2009-03-17
申请号：US11364394
申请日：2006-02-28
申请人： John S. Yu , Peter Kabos , Moneeb Ehtesham
发明人： John S. Yu , Peter Kabos , Moneeb Ehtesham
IPC分类号： A61K48/00
CPC分类号： C12N5/0623 , A61K35/12 , A61K38/00 , A61K48/00 , C12N2501/11 , C12N2501/115 , C12N2506/11 , C12N2506/1353 , C12N2510/00
摘要： A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.
摘要翻译：描述了从全骨髓产生临床显着体积的神经祖细胞的方法。大量的骨髓细胞可以在补充有成纤维细胞生长因子-2（FGF-2）和表皮生长因子（EGF）的培养物中生长。本发明的其它方法涉及利用以这种方式培养的神经祖细胞来治疗各种神经病理学病症，并将靶向特定基因转染的细胞靶向递送给病变组织或受损组织。

5. 发明申请

US20080274086A1 Use of Cxcr4 Protein Expression on the Surface of Stem Cells as a Marker for Tumor Tropic Potential 审中-公开
标题翻译：在干细胞表面上使用Cxcr4蛋白表达作为肿瘤回旋电位的标记物
公开(公告)号：US20080274086A1
公开(公告)日：2008-11-06
申请号：US10598468
申请日：2004-09-17
申请人： John S. Yu , Moneeb Ehtesham
发明人： John S. Yu , Moneeb Ehtesham
IPC分类号： A61K35/12 , C12N5/08 , A61P35/00 , C12Q1/68
CPC分类号： C12N5/0623 , C12N2501/11 , C12N2501/115 , G01N33/5017 , G01N33/5073 , G01N2333/715
摘要： The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1.
摘要翻译：本发明涉及肿瘤热带干细胞，特别涉及神经干细胞，以及它们作为治疗性基因产物转移至肿瘤灶的递送载体的用途。基于显示CXCR4受体的干细胞或对趋化因子SDF-1的亲和力，选择具有肿瘤嗜性潜能的干细胞。干细胞可能另外表现出星形细胞祖细胞特征的标志物。干细胞可以作为治疗方案的一部分施用，包括趋化因子SDF-1。

6. 发明授权

US08871211B2 Cancer vaccines and vaccination methods 有权
标题翻译：癌症疫苗和疫苗接种方法
公开(公告)号：US08871211B2
公开(公告)日：2014-10-28
申请号：US11863990
申请日：2007-09-28
申请人： John S. Yu , Gentao Liu , Keith L. Black
发明人： John S. Yu , Gentao Liu , Keith L. Black
IPC分类号： A61K39/00 , C12N5/0784 , A61K35/12
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/545 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/2304 , C12N2501/25 , C12N2501/998 , C12N2506/11
摘要： Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
摘要翻译：本文提供了通过树突状细胞疫苗接种治疗癌症（如神经癌）的方法和组合物。

7. 发明授权

US08097256B2 Cancer vaccines and vaccination methods 有权
标题翻译：癌症疫苗和疫苗接种方法
公开(公告)号：US08097256B2
公开(公告)日：2012-01-17
申请号：US11864177
申请日：2007-09-28
申请人： John S. Yu , Gentao Liu , Keith L. Black
发明人： John S. Yu , Gentao Liu , Keith L. Black
IPC分类号： A61K39/00 , C12P21/00
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/545 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/2304 , C12N2501/25 , C12N2501/998 , C12N2506/11
摘要： Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
摘要翻译：本文提供了通过树突状细胞疫苗接种治疗癌症（如神经癌）的方法和组合物。

8. 发明授权

US06774119B1 HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)-DERIVED VECTOR FOR SELECTIVELY INHIBITING MALIGNANT CELLS AND METHODS FOR ITS USE TO TREAT CANCERS AND TO EXPRESS DESIRED TRAITS IN MALIGNANT AND NON-MALIGNANT MAMMALIAN CELLS 有权
标题翻译：用于选择性抑制恶性细胞的HERPES SIMPLEX病毒1型（HSV-1）载体及其用于治疗癌症并在恶性和非恶性肿瘤细胞中表达所需的病原体的方法
公开(公告)号：US06774119B1
公开(公告)日：2004-08-10
申请号：US09299817
申请日：1999-04-26
申请人： Steven L. Wechsler , Anthony B. Nesburn , Guey-Chuen Perng , John S. Yu , Keith L. Black
发明人： Steven L. Wechsler , Anthony B. Nesburn , Guey-Chuen Perng , John S. Yu , Keith L. Black
IPC分类号： A61K4800
CPC分类号： C12N7/00 , A61K39/00 , A61K48/00 , C07K14/005 , C12N15/86 , C12N2710/16622 , C12N2710/16643 , C12N2710/16661
摘要： Disclosed is a method of selectively inhibiting the growth of malignant cells in mammals, including humans. The method selectively inhibits the growth of malignant cells of all varieties, and is particularly useful in treating brain tumors and other malignancies of the central nervous system. The method employs HSV-1-derived vectors containing a DNA having a deletion in both copies of the LAT gene and both copies of the ICP34.5 gene of HSV-1. The vectors are delivered to malignant cells either in vivo or in vitro, in accordance with the method. The HSV-1-derived expression vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid having a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-&ggr;. A method of expressing in a mammalian cell a gene encoding a preselected protein, a method of treating a genetic defect, and a method of detecting an HSV-1 expressing cell also employ vectors of the present invention that contain at least one transcriptional unit of a constitutive LAT promoter operatively linked to and controlling the transcription of a gene encoding a preselected protein. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, useful for practicing the methods, and mammalian cells containing the HSV-derived vectors.
摘要翻译：公开了一种选择性抑制包括人在内的哺乳动物中恶性细胞生长的方法。该方法选择性地抑制所有品种的恶性细胞的生长，并且特别可用于治疗中枢神经系统的脑肿瘤和其他恶性肿瘤。该方法使用含有两个拷贝的LAT基因和HSV-1的ICP34.5基因的两个拷贝的具有缺失的DNA的HSV-1衍生载体。根据该方法，在体内或体外将载体递送至恶性细胞。 HSV-1衍生的表达载体是非神经毒性的，并且不会从潜伏期自发地再激活，并且它们任选地含有功能性HSV胸苷激酶基因，其可以增强用喷昔洛维或阿昔洛韦进行药物治疗的癌症的有效性。或者，HSV-1衍生的载体含有至少一个LAT启动子序列的转录单位，该转录单位可操作地连接到具有编码对表达载体的细胞有毒的多肽的核苷酸序列的核酸，例如人类干扰素-γ。在哺乳动物细胞中表达编码预选蛋白质的基因，治疗遗传缺陷的方法和检测表达HSV-1的细胞的方法的方法也采用本发明的载体，其含有至少一个转录单位组成型LAT启动子与编码预选蛋白质的基因的转录有效连接并控制其转录。此外，公开了用于在哺乳动物细胞中表达编码用于实施该方法的预选蛋白质的基因和含有HSV衍生载体的哺乳动物细胞的试剂盒。

9. 发明授权

US09433667B2 Cancer vaccines and vaccination methods 有权
公开(公告)号：US09433667B2
公开(公告)日：2016-09-06
申请号：US13327125
申请日：2011-12-15
申请人： John S. Yu , Gentao Liu , Keith L. Black
发明人： John S. Yu , Gentao Liu , Keith L. Black
IPC分类号： A61K39/00 , C12N5/0784 , A61K35/12
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/545 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/2304 , C12N2501/25 , C12N2501/998 , C12N2506/11
摘要： Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.

10. 发明申请

US20140140931A1 ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER 审中-公开
标题翻译：抗氧化剂，包含治疗药物的神经保护和抗原性纳米颗粒在AMPHIPHILIC间隔剂或AMPHIPHILIC聚合物
公开(公告)号：US20140140931A1
公开(公告)日：2014-05-22
申请号：US14232871
申请日：2012-07-27
申请人： John S. Yu , Bong Seop Lee
发明人： John S. Yu , Bong Seop Lee
IPC分类号： A61K47/48 , A61K49/00
CPC分类号： A61K47/55 , A61K9/5123 , A61K38/00 , A61K49/0032 , A61K49/0052
摘要： This invention relates to antioxidant, neuroprotective and antineoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer. Methods of synthesizing the antioxidant derivatives of camptothecin and anti-oxidant derivatives of camptothecin analogs, NSAIDs and statins, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant, neuroprotective and anti-neoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these neuroprotective and anti-neoplastic nanoparticles for the preparation of delivery devices of other pharmaceuticals and/or drugs.
摘要翻译：本发明涉及包含在两亲性间隔物或两亲性聚合物上的治疗剂的抗氧化剂，神经保护和抗肿瘤纳米颗粒。合成喜树碱的抗氧化剂衍生物和喜树碱类似物的抗氧化衍生物，NSAIDs和他汀类药物的自发乳化或纳米沉淀以产生抗氧化剂，神经保护和抗肿瘤纳米颗粒的方法，其包含在两亲性间隔基或两亲性聚合物上的治疗剂及其还提供用于治疗癌性疾病。本发明的另一方面是这些神经保护和抗肿瘤纳米颗粒在制备其它药物和/或药物的递送装置中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式